{"id":"W4376613563","doi":"10.1016/j.esmoop.2023.101385","title":"196P Efficacy and safety of first-line (1L) ribociclib (RIB) + letrozole (LET) in patients (pts) with de novo metastatic disease and late recurrence from (neo)adjuvant therapy (tx) in MONALEESA (ML)-2","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"Bristol-Myers Squibb; Samsung; Genentech; Daiichi-Sankyo; Eisai; Novartis Pharmaceuticals Corporation; Ascentage Pharma; Argenx; Syndax Pharmaceuticals; Mirati Therapeutics; Les Laboratories Pierre Fabre; TG Therapeutics; AstraZeneca; Novocure; Daiichi Sankyo Europe; Gilead Sciences; Sanofi; Amgen; Pfizer; G1 Therapeutics; Ipsen Biopharmaceuticals; Celgene; Carrick Therapeutics; Eli Lilly and Company","keywords":"Medicine; Internal medicine; Letrozole; Adjuvant; Gastroenterology; Progression-free survival; Surgery; Chemotherapy; Cancer; Breast cancer; Oncology; Aromatase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004525513,0.0002386361,0.0007557879,0.000179739,0.0001143643,0.000391256,0.0002233966,0.0003442867,0.001369009],"category_scores_gemma":[0.0005081068,0.0001421193,0.0006862712,0.0001708778,0.000175232,0.0002213431,0.0001682993,0.0005989145,0.0002797321],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005349493,"about_ca_system_score_gemma":0.0004070637,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007469182,"about_ca_topic_score_gemma":0.00260133,"domain_scores_codex":[0.9998456,0.00006635243,0.0000122825,0.00002529626,0.00001853907,0.00003188988],"domain_scores_gemma":[0.9997992,0.00003849301,0.00005938987,0.00001761209,0.00001092393,0.00007439042],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6288294,0.008288492,0.06619032,0.0006315141,0.001844356,0.0005975712,0.000235775,0.002885876,0.07284012,0.0002575495,0.002297771,0.2151013],"study_design_scores_gemma":[0.1333325,0.4593997,0.3750124,0.00009934214,0.002438802,0.00146039,0.0001975357,0.004876283,0.01560366,0.0002917256,0.00721566,0.00007194102],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9979564,0.001111126,0.00005821287,0.00008305444,0.00001421928,0.00004371972,0.0002754697,0.00001201804,0.0004456537],"genre_scores_gemma":[0.9981835,0.0004103432,0.00008913828,0.0001165495,0.00002892583,0.00005467236,0.0005138913,0.000003737792,0.0005990708],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001369009,"threshold_uncertainty_score":0.004579782,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02612377177042233,"score_gpt":0.3038011649631449,"score_spread":0.2776773931927226,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}